Biology and therapeutic potential of GLP-1 in the treatment of diabetes

Chee W. Chia, Josephine M. Egan

Research output: Contribution to journalReview articlepeer-review

Abstract

Glucagon-like peptide-1 (GLP-1) is a hormone secreted from enteroendocrine L-cells of the intestine in response to food. It has many properties deemed beneficial in type 2 diabetes but it is subject to rapid enzymatic degradation, and thus, it is not suitable as a long-term treatment. Synthetic enzyme-resistant GLP-1 analogs that reproduce the biological effects of GLP-1 are under intense investigation. This review aims at providing a summary of the properties of GLP-1 and the development of its analogs for treatment of type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)295-301
Number of pages7
JournalDrug Discovery Today: Disease Mechanisms
Volume2
Issue number3
DOIs
StatePublished - 2005

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint Dive into the research topics of 'Biology and therapeutic potential of GLP-1 in the treatment of diabetes'. Together they form a unique fingerprint.

Cite this